KD Logo

Recent Insider Activity Suggests Potential Gains for Sagimet Biosciences Inc (SGMT)

Sagimet Biosciences Inc’s recently made public that its Executive Chairman Kemble George unloaded Company’s shares for reported $74830.0 on Jul 23 ’24. In the deal valued at $3.17 per share,23,625 shares were sold. As a result of this transaction, Kemble George now holds 118,693 shares worth roughly $0.59 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Martins Eduardo Bruno sold 8,357 shares, generating $25,910 in total proceeds. Upon selling the shares at $3.10, the Chief Medical Officer now owns 81,213 shares.

Before that, Rozek Elizabeth sold 10,914 shares. Sagimet Biosciences Inc shares valued at $33,830 were divested by the General Counsel and CCO at a price of $3.10 per share. As a result of the transaction, Rozek Elizabeth now holds 160,506 shares, worth roughly $0.79 million.

Oppenheimer initiated its Sagimet Biosciences Inc [SGMT] rating to an Outperform in a research note published on December 06, 2024; the price target was $30. A number of analysts have revised their coverage, including UBS’s analysts, who began to cover the stock in mid November with a ‘”a Buy”‘ rating. Goldman also remained covering SGMT and has decreased its forecast on June 28, 2024 with a “Neutral” recommendation from previously “Buy” rating. H.C. Wainwright started covering the stock on May 02, 2024. It rated SGMT as “a Buy”.

Price Performance Review of SGMT

On Tuesday, Sagimet Biosciences Inc [NASDAQ:SGMT] saw its stock fall -0.60% to $4.94. Over the last five days, the stock has lost -17.00%. Sagimet Biosciences Inc shares have fallen nearly -9.04% since the year began. Nevertheless, the stocks have fallen -10.69% over the past one year. While a 52-week high of $20.71 was reached on 01/22/24, a 52-week low of $2.39 was recorded on 08/14/24. SMA at 50 days reached $5.29, while 200 days put it at $4.27.

Levels Of Support And Resistance For SGMT Stock

The 24-hour chart illustrates a support level at 4.84, which if violated will result in even more drops to 4.74. On the upside, there is a resistance level at 5.02. A further resistance level may holdings at 5.10. The Relative Strength Index (RSI) on the 14-day chart is 47.78, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.06, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 71.97%. Stochastics %K at 28.67% indicates the stock is a holding.

How much short interest is there in Sagimet Biosciences Inc?

A steep rise in short interest was recorded in Sagimet Biosciences Inc stocks on 2024-10-31, growing by 2.2 million shares to a total of 4.17 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 1.97 million shares. There was a rise of 52.74%, which implies that there is a positive sentiment for the stock.

The most recent change occurred on March 25, 2024 when Leerink Partners began covering the stock and recommended ‘”an Outperform”‘ rating along with a $26 price target.

Most Popular